Rishika Motiani, MD
Infectious Disease · Florence, SCNPI 1538302245
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 80.2% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2019 at $28,058 and has fallen 97.5% since, to $688 in 2025. Among infectious disease clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 302 payments — averaging $142.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$34K
- Viiv Healthcare Company$6K
- AbbVie$416
- Janssen Products, LP$298
- Novo Nordisk$287
- GSK$222
- plus $1K from 27 others
What the payments were for
- Consulting fees$12,27029%
- Speaking & faculty fees$20,69048%
- Travel & lodging$5,00512%
- Food & beverage$4,73511%
- Education$2981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 106 | $34,469 |
| Viiv Healthcare Company | 59 | $6,144 |
| AbbVie(2 entities) | 24 | $416 |
| Janssen Products, LP | 3 | $298 |
| Novo Nordisk | 19 | $287 |
| GSK | 13 | $222 |
| Johnson & Johnson | 12 | $141 |
| Merck | 9 | $119 |
| Lilly USA, LLC | 7 | $104 |
| Theratechnologies Inc. | 7 | $103 |
| AstraZeneca | 5 | $76 |
| Phathom Pharmaceuticals, Inc. | 6 | $65 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Amgen | 2 | $40 |
| Dynavax Technologies Corporation | 2 | $40 |
| Xeris Pharmaceuticals, Inc. | 2 | $39 |
| Paratek Pharmaceuticals, Inc. | 2 | $36 |
| Boehringer Ingelheim | 2 | $35 |
| Bayer | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Ardelyx, Inc. | 1 | $30 |
| Novartis | 2 | $27 |
| Insmed, Inc. | 2 | $27 |
| Napo Pharmaceuticals Inc | 2 | $24 |
| Averitas Pharma Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Exact Sciences | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Abbott | 1 | $15 |
| Renalytix AI, Inc. | 1 | $15 |
| Cequr Corporation | 1 | $14 |
| Vyera Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$42,997 in reported general payments places this provider in the 95th percentile of 102 infectious disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 156 | $604,667 |
| JardianceEmpagliflozin | 138 | $158,789 |
| OzempicSemaglutide | 130 | $148,077 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 38 | $144,870 |
| TrulicityDulaglutide | 68 | $75,013 |
| EliquisApixaban | 73 | $66,046 |
| TivicayDolutegravir Sodium | 22 | $57,378 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $45,212 |
| MounjaroTirzepatide | 27 | $39,084 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $37,350 |
| LinzessLinaclotide | 33 | $37,247 |
| DovatoDolutegravir Sodium/Lamivudine | 12 | $32,452 |
| JanuviaSitagliptin Phosphate | 20 | $30,303 |
| FarxigaDapagliflozin Propanediol | 41 | $29,687 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $26,725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $34,469 | $749,537194 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $35 | $166,687153 claims |
| Novo NordiskOzempic | $287 | $148,077130 claims |
| Viiv Healthcare CompanyTivicay, Triumeq, Dovato | $6,144 | $135,04146 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $104 | $114,09895 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $76 | $53,541107 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $222 | $50,29870 claims |
| AbbVieLinzess, Namzaric | $416 | $45,56647 claims |
| MerckJanuvia | $119 | $30,30320 claims |
| Johnson & JohnsonXarelto, Invokana | $141 | $23,71332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 102 infectious disease providers in South Carolina.
Other infectious disease in Florence
- Julio ArroyoFlorence$5K
- Temujin ChavezFlorence$3K
- Ramesh BharadwajFlorence$1K
- Timothy HenkelHilton Head Island$1.8M
- Toby FugateCharleston$136K
- John McKinnonCharleston$85K
- John SchrankGreenville$74K
- John GnannCharleston$39K
- John SamiesOrangeburg$18K
- Akinwale OlatosiCamden$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.